Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Brilaroxazine
RP5063 · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| Brilaroxazine | DRUG | RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride. |
| Placebo | OTHER | RP5063 matching Placebo |
| RP5063 | DRUG | daily |
| aripiprazole | DRUG | daily |
RP5063 is an investigational small molecule being developed for the treatment of acute schizophrenia. It is also being studied in patients with schizoaffective disorder. The drug is currently in Phase 2 clinical development and has not yet been approved by regulatory authorities.
RP5063 is being developed by Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RVPH. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for psychiatric conditions.
RP5063 is currently in Phase 2 clinical development. A Phase 2 clinical trial has been completed, and the drug remains investigational. It has not received regulatory approval and is still undergoing clinical evaluation for the treatment of acute schizophrenia and schizoaffective disorder.
RP5063 has one completed clinical trial registered under NCT01490086, titled 'RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder.' This Phase 2 study enrolled 234 participants with acute schizophrenia or schizoaffective disorder. The trial has been completed, and no active trials are currently listed.
RP5063 is the primary name used for this investigational compound. No alternative names have been reported in the clinical trial data. The drug is being studied under this identifier in the completed Phase 2 trial for schizophrenia and schizoaffective disorder.